PFE must have made some price concessions that GSK was simply unwilling to make to lose a contract in their home country This may be a prelude to how MRNA will also try and compete I still think GSK has the best product profile but only by a little bit, and PFE is an easier shot to tolerate (but *might have more GBS surprisingly, which might be MRNA's marketing schtick since they haven't had a case)
Market Data 
Markets 
AI
